Dr Reddy's gearing up to get substantial slice of Revlimid generic opportunity in US

Revlimid is a top-selling cancer drug from Bristol Myers Squibb. Its generic form, called lenalidomide, is seen as Dr Reddy's most anticipated product for FY23. Last year, Revilimid had raked in $8 billion for Bristol Myers in US sales. It represents a sizable opportunity for Dr Reddy's which is facing pricing pressure and competition in certain key products, such as generics of Suboxone and Vasopressin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Mt4hXe0
via IFTTT